Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493192 | 0.97 | ITGB1 (0.36) | ITGB1ITGA4CALCRLF2XIAP | |
| SCHEMBL30730414 | 0.90 | CALCRL (0.38) | ITGB1ITGA4CALCRLF2XIAP | |
| SCHEMBL29832674 | 0.88 | XIAP (0.37) | CALCRLF2XIAPNTMT1DPP4 | |
| SCHEMBL4258292 | 0.86 | F2 (0.39) | ITGB1ITGA4F2NTMT1AVPR1A | |
| SCHEMBL31031470 | 0.86 | CAPN1 (0.38) | ITGB1ITGA4F2NTMT1DPP4 | |
| SCHEMBL29832543 | 0.85 | CALCRL (0.36) | CALCRLXIAPDPP4PREPFAP | |
| SCHEMBL29816594 | 0.85 | PTGS1 (0.41) | ITGB1ITGA4F2NTMT1REN | |
| SCHEMBL30138992 | 0.84 | CAPN1 (0.40) | ITGB1ITGA4F2NTMT1DPP4 | |
| SCHEMBL26389253 | 0.83 | DPP4 (0.40) | ITGB1ITGA4F2XIAPNTMT1 | |
| SCHEMBL29699495 | 0.83 | KMT2A (0.43) | ITGB1ITGA4XIAPOXTRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086844-A1 | ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET | 正大天晴药业集团股份有限公司 | 2026-04-30 | — | — | WO | disclosed |
| US-12612468-B2 | Engineering the hinge region to drive antibody dimerization | AMGEN INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12594342-B2 | Method of conjugation of Cys-mAbs | AMGEN INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4703390-A1 | MULTISPECIFIC ANTIBODY TARGETING C-MET | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4703384-A1 | BISPECIFIC ANTIBODY TARGETING G PROTEIN-COUPLED RECEPTOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | AMGEN INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250136653-A1 | FGF21 Mutants and Uses Thereof | AMGEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250121056-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | AMGEN INC. | 2025-04-03 | — | — | US | disclosed |
| CN-119431599-A | Engineering hinge regions to drive antibody dimerization | 美国安进公司 | 2025-02-14 | — | — | CN | disclosed |
| US-11535659-B2 | Engineered polypeptides having enhanced duration of action | AMRYT PHARMACEUTICALS INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022266467-A2 | RECOMBINANT HISTONE POLYPEPTIDE AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022225921-A1 | BALANCED CHARGE DISTRIBUTION IN ELECTROSTATIC STEERING OF CHAIN PAIRING IN MULTI-SPECIFIC AND MONOVALENT IGG MOLECULE ASSEMBLY | AMGEN INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4050026-A1 | METHOD OF OBTAINING OR IDENTIFYING ONE OR MORE COMMON LIGHT CHAINS FOR USE IN PREPARING A MULTISPECIFIC ANTIBODY | Adimab, LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022166728-A1 | BISPECIFIC ANTIBODY | 正大天晴药业集团股份有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20220235148-A1 | ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION | AMGEN INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022076474-A2 | RATIONAL SELECTION OF BUILDING BLOCKS FOR THE ASSEMBLY OF MULTISPECIFIC ANTIBODIES | AMGEN INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3976643-A2 | ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION | Amgen Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114174344-A | Engineering hinge region to drive antibody dimerization | 美国安进公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11266744-B2 | Modified Fc molecules | AMGEN INC. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594342-B2 | Method of conjugation of Cys-mAbs | TST, PTMS, TMT1A | ITGB1 276/4885ITGA4 325/4885CALCRL 2602/4885 |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | CTSD, DNPEP, CTSZ | ITGB1 2423/4885ITGA4 2463/4885CALCRL 1684/4885 |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | CBS, GCLC, PTMS | ITGB1 462/4885ITGA4 708/4885CALCRL 1378/4885 |
| US-20250121056-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | GIPR, GLP1R, GCGR | ITGB1 3805/4885ITGA4 4184/4885CALCRL 319/4885 |
| US-11535659-B2 | Engineered polypeptides having enhanced duration of action | IAPP, HDGF, FABP1 | ITGB1 4722/4885ITGA4 4855/4885CALCRL 1405/4885 |
| US-11266744-B2 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | ITGB1 869/4885ITGA4 514/4885CALCRL 2230/4885 |
| US-12612468-B2 | Engineering the hinge region to drive antibody dimerization | IGLV6-57, FCGR3B, FCGR2A | ITGB1 735/4885ITGA4 2834/4885CALCRL 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.